Eric Morrow told his doctor about his family history of prostate cancer and asked if he needed testing. His doctor said no.

A study led by Cancer Center at Illinois (CCIL) member Jason Ridlon, associate professor of animal sciences in the College of ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

How to foster inclusivity and cultural sensitivity when caring for diverse populations with prostate cancer, to give ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

In the benign cohort, initial biopsies showed 37% of patients had ASAP with or without high-grade prostatic intraepithelial neoplasia (HGPIN), while 28% had HGPIN only, and 52% had neither ASAP or ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

In March, the UK marked Prostate ... cancer, and that it was a “viable, efficient alternative” for patients. Elsewhere, several other HCPs drew attention to promising new treatment options ...

Investigators present 48 month follow-up data from a phase 2b trial on padeliporfin vascular-targeted photodynamic therapy for intermediate-risk prostate cancer.